Cover Story
Clinical
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- How the 2024 elections can impact cancer policy
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- ACS board member Wayne Frederick steps in as interim CEO, replacing Karen Knudsen
National search will be conducted - Before the Olympics were smoke-free, tobacco brand deals ran rampant
- University of Hawai‘i Cancer Center receives NCI designation with “outstanding” score
- Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo